Casopitant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Casopitant
Casopitant.png
Systematic (IUPAC) name
(2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
Clinical data
Legal status ?
Identifiers
CAS number 414910-27-3
ATC code A04AD13
PubChem CID 23725089
ChemSpider 25069049
UNII 3B03KPM27L YesY
ChEMBL CHEMBL2107320
Chemical data
Formula C30H35F7N4O2 
Mol. mass 616.26 g/mol
 YesY (what is this?)  (verify)

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]

See also[edit]

References[edit]

  1. ^ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612. 
  2. ^ "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa". London: EMEA. 13 October 2009. Retrieved 21 December 2009.